Table 3.
Anti-tumor response after 12 weeks of E4 treatment according to RECIST criteria
| Evaluation | 20 mg E4 | 40 mg E4 | 60 mg E4 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients | 1 | 2 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Evaluation of target lesions | PD | SD | CR | SD | SD | SD | PD | PD | PD |
| Evaluation of non-target lesions | PD | Non-CR/non-PD | Non-CR/non-PD | Non-CR/non-PD | Non-CR/non-PD | Non-CR/non-PD | PD | – | PD |
| New lesions | Yes | No | No | No | No | No | Yes | Yes | No |
| Response type | PD | SD | CR | SD | SD | SD | PD | PD | PD |
| Response | No | Yes | Yes | Yes | Yes | Yes | No | No | No |
E4 estetrol, CR complete response, SD stable disease, PD progressive disease